PHVS Pharvaris N.V.
$33.58▲ +2.32%
Healthcare
Other
Volume 877.9K
Avg Volume (10D) 639.5K
Key Metrics & Fundamentals
Market Cap
$2.36B
P/E Ratio
–
Div Yield
0.00%
52W Range
21.02 - 43.25
% vs 50 MA
-0.42%
% vs 200 MA
8.48%
RSI-14
59.9
MACD Histogram
+0.5400
Beta (1Y vs SPY)
0.88
Free Cash Flow
-$37.83M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$52.25M
COGS
–
Operating Exp
$50.79M
Operating Income
-$50.79M
EBIT
-$50.79M
Pretax Income
-$47.24M
Net Income
-$47.84M
EPS (Diluted)
-0.70
Price & Volume History
Loading chart…
Recent News
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
GlobeNewswire · Oct 29, 2026 6:50 AM ET
Bank of America backs Pharvaris on breakthrough for rare swelling disease
TheStreet · Oct 26, 2026 7:00 PM ET
Pharvaris Shares Rise After BofA Securities Upgrade
MT Newswires · Oct 23, 2026 2:23 PM ET
Pharvaris Pullback Presents Opportunity Ahead of 2027 Milestones, BofA Says
MT Newswires · Oct 23, 2026 10:47 AM ET
Update: BofA Securities Upgrades Pharvaris to Buy From Neutral, $44 Price Target
MT Newswires · Oct 23, 2026 10:03 AM ET
Norwegian downgraded, Skydance upgraded: Wall Street's top analyst calls
The Fly · Oct 23, 2026 9:57 AM ET
BofA Securities Upgrades Pharvaris to Buy From Neutral
MT Newswires · Oct 23, 2026 7:08 AM ET
BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?
Insider Monkey · Oct 15, 2026 2:05 PM ET
Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial
MT Newswires · Oct 9, 2026 4:09 AM ET
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
GlobeNewswire · Oct 8, 2026 6:35 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See PHVS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.